FA
ACAD icon

Friess Associates’s Acadia Pharmaceuticals ACAD Stock Holding History

Friess Associates’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-267,164
Closed -$12.9M – 107
2020
Q2 		$12.9M Buy
267,164
+93,190
+54% +$4.47M 1.21% 41
2020
Q1 		$7.35M Buy
+173,974
New +$7.17M 0.73% 50

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Friess Associates's ACAD Position: Q3 2020 in Review

Friess Associates sold out of Acadia Pharmaceuticals (ACAD) in Q3 2020, closing a stake of 267,164 shares — an estimated $12.9M sold.

Friess Associates first reported a position in ACAD in Q1 2020 and held it in 2 quarters. The position peaked at $12.9M in Q2 2020. 267 funds tracked by Wall St. Rank hold ACAD as of Q3 2020.

  • Friess Associates reported no remaining Acadia Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Friess Associates sold 267,164 Acadia Pharmaceuticals shares in Q3 2020, an estimated $12.9M.
  • Friess Associates first reported a position in Acadia Pharmaceuticals in Q1 2020 and held it in 2 quarters.
  • Friess Associates's Acadia Pharmaceuticals position peaked at $12.9M in Q2 2020.
  • 267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2020.

Based on Friess Associates's 13F filing for Q3 2020, filed 13 Nov 2020.